Data dive: The 5 biggest barriers to ending the COVID-19 pandemic for good

Jump to

    Ending the pandemic everywhere

    The threat of COVID-19 has been with us for over two years and the world is finally coming together around a coherent strategy to end the crisis: to vaccinate at least 70% of people across each country-income category by September 2022 and protect against the economic aftershocks of the pandemic.

    However, doing so will require a massive shift in momentum – one that urgently directs resources toward the countries that are furthest behind in the response.

    At the current rate, it could take over a decade before low-income countries achieve vaccination levels similar to high-income countries. Unless we beat the virus everywhere, we face the prospect of extending the lifetime of the pandemic throughout the next decade – and with it the devastating aftershocks that have wreaked havoc on the global economy.

    Failure to address this increasingly man-made crisis will be felt in every country and community in the world. It’s undeniably in the common interests of people everywhere to succeed in this mission – so what are the obstacles blocking progress? And how can we remove them?

    Barrier 1: Wealthy countries have met the global vaccination target and are still hoarding doses.


    About 40% of the world’s population — 3.0 billion people, predominantly in low- and lower-middle income countries — have not received any vaccine doses, leaving them completely exposed to the virus. And yet, so far 18.3 times as many people in wealthier countries have received a booster shot as people in low-income countries got their first vaccine dose.


    In theory we have enough doses to vaccinate the whole world. We just aren’t getting them to the people that need them most. Indeed, boosters divert supply from the most urgent area of need — administering first and second doses in low- and lower-middle income countries. And while evidence shows that the body’s immune response to COVID-19 vaccines will drop over time and boosters help protect against severe infection from highly transmissible variants, the relative protection from one or two doses is still significantly higher than zero doses. Therefore, it is critical that the distribution of first and second doses everywhere in the world continues to be prioritised alongside boosters. As we have seen with both the Delta and Omicron variants, the longer we wait to vaccinate the world, the greater the threat to us all.


    Boosters are important, but we must continue to prioritise first and second doses for the people who need vaccines most, starting with health workers and the most vulnerable people in low-income countries. Booster programs in high-income countries must not come at the expense of sharing doses that have already been committed to low- and lower-middle income countries, and partnering with COVAX and AVAT to ensure doses purchased can be delivered.

    Barrier 2: The mechanisms to purchase and distribute doses to lower-income countries continue to be undermined.


    High-income countries have purchased 2.6 times more doses than COVAX even though COVAX is serving a population three times the size of that in high-income countries. Similarly, high-income countries have purchased more than 20 times more doses than the African Union’s COVID-19 Africa Vaccine Acquisition Task Team (AVAT), even though they are both serving populations similar in size.


    These disparities in vaccine procurement are not an accident. High-income countries had the purchasing power to be first at the table with pharmaceutical companies giving them first dibs on the global supply. Conversely, despite issuing its first funding appeal for an initial $2 billion to start securing doses for lower-income countries in June 2020, COVAX did not secure signed donor agreements for this amount until December 2020 and the cash didn’t arrive until February 2021. As a result, high-income countries cumulatively signed 48 deals with pharmaceutical companies before the cash had even landed in COVAX’s coffers, limiting its ability to negotiate. This purchasing power also gives pharmaceutical companies more incentive to prioritize deals with richer countries. Even when they had funds to buy vaccines, AU officials have complained that they still could not get companies to do deals with them. Similar trends are beginning to emerge as therapeutics become approved for use around the world. High income countries are beginning to purchase millions of courses of approved therapeutics, while many low and lower income countries must rely on mechanisms such as the Medicines Patent Pool.


    At least US $52 billion is needed to fund the global response in 2022, with at least $27.7bn, or 53%, needed to fund mechanisms such as ACT-A.. G20 countries and other donors must learn the lesson from the last two years and act faster to allow these mechanisms to deliver on their mandates; dose sharing and funding commitments must be made by the end of Q1 2022 and delivered in full by the end of Q2 2022 at the latest.

    Barrier 3: Manufacturing capacity and know-how is concentrated in too few places globally.


    The World Health Organization is trying to reverse engineer Moderna’s vaccine because the company refuses to share its recipe or technology to scale up global production, and production capacity is limited globally.

    Companies’ refusal to share their technology and recipes means we’re not making as many vaccines as possible, in as many places as possible. Without more knowledge sharing alongside more localized production, low-income countries are dependent on a broken vaccine market and increasingly volatile global supply chains. With the right investment and cooperation, mRNA vaccines can be made much faster than traditional vaccines. Last September, BioNTech bought a plant in Germany with 300 staff that had never worked with mRNA technology, and in six months, they were producing millions of mRNA vaccines a week. If mRNA manufacturers refuse to share their tech and recipes, and refit other plants elsewhere, it reduces the number of options for procurement, and gives companies more leverage to negotiate higher prices with countries.

    G20 countries should invest in regional manufacturing, encourage mRNA manufacturers to share technology with the World Health Organization and local manufacturers, and temporarily waive intellectual property rights at the World Trade Organization.

    Barrier 4: Economic aftershocks are crippling the global economy, undermining everyone’s ability to fight the pandemic and hobbling poorer countries for years to come.


    • Global economic growth projections for 2022 suggest a deceleration from the 2021 bounceback, with global growth this year expected to be about 4.1% down from 5.5% in 2021, a 25% drop.
    • The pandemic has caused the first rise in extreme poverty in 2 decades; 2020 saw 100 million more people pushed into extreme poverty.
    • Advanced economies spent trillions bolstering their economies against the worst effects of the pandemic – more than 18% of their GDP. But developing countries simply didn’t have the same capacity, spending an average of less than 2% of their GDP protecting their economies.
    • Africa needs at least $285 billion in additional funding just to respond to the pandemic over the next few years and at least $500 billion to get back on track – the global economic response to date, despite nice words from many leaders, has failed to come even close to meeting that need.
    • There’s a debt crisis happening right now in Africa – in 2020, the debt burden grew to over $625 billion. Half of low-income countries are either in or at high risk of debt distress but the next three years will see them pay $35 billion in debt service.


    The pandemic hit everyone, everywhere hard. We all felt the impact in our lives, our jobs, and our economies. But the recovery is following a different path where richer countries are back to their economic normal right now while poorer countries face years of slowdown. Without the same capacity to respond, poorer countries are more exposed to the virus and the economic effects. And that is bad for everyone as the virus continues to circulate and dampen economic recovery and growth prospects, hampers global trade, kills off tourism, disrupts supply chains, and puts us all at risk of new and more dangerous variants that will start the whole cycle again.


    It’s in all our interests to end the pandemic and the economic crisis it continues to drive. And we have the means to do this.

    • Advanced economies should recycle their allocations of Special Drawing Rights (SDRs), which are currently lying unused, to low- and vulnerable middle-income countries. The G7 and G20 promised to deliver $100 billion in recycled SDRs and this is a commitment that must be met, with a clear roadmap to recycling more.
    • Multilateral development banks could be key engines of a truly global economic restart – the World Bank and African Development Bank, in particular, should work with the IMF to swiftly develop viable options for SDR channeling.

    Barrier 5: Vaccine deliveries don’t match commitments and have been unreliable and hard to predict.


    G20 countries have committed to share over 2.7 billion doses through 2022, but only 943 have been delivered as of 10 February 2022. Only a small handful of countries met their dose sharing commitments for 2021. . And while deliveries increased significantly in the latter half 2021, it is not clear when these commitments will be fulfilled.

    Vaccine delivery schedules are considered proprietary so there are no public benchmarks to hold companies accountable to; vaccines arrive when they arrive. Vaccines are also being delivered with short shelf life and are rapidly expiring after arriving in countries.


    Without a predictable flow of vaccines, it’s impossible for countries to plan for effective vaccination campaigns. Low- and lower-middle income countries, which currently have to rely heavily on dose sharing, may only have a few days’ notice for when and where vaccines will arrive, and what kind of vaccine they can expect. Wealthier countries that have made dose sharing commitments are increasingly pointing to pharmaceutical companies’ lack of transparency as the reason they are not sharing doses more quickly. This lack of predictability leads to vaccines being wasted and fewer people being protected.


    To improve predictability in the global vaccine supply chain, all G20 countries that have already committed to share doses should release a plan for how and when they will fulfill these commitments. Plans must include what type of vaccine will be shared, when they will be delivered (by month), and who the intended recipient is (e.g. COVAX, AVAT, bilateral). All doses that are reallocated should go to low- and lower-middle income countries. For at least the next 12 months, companies should publicly publish monthly production projections and delivery schedules to help countries better plan to receive and share doses. Donor governments and manufacturers must adhere to the principles laid out by COVAX, AVAT, and Africa CDC in November 2021. G20 countries and other donors must fulfill their remaining dose-sharing commitments in full by September 2022.



    We have all the tools needed to beat this virus, end the pandemic and kick start a global economic recovery. We just aren’t using them. And while that remains the case, we prolong the lifetime of this crisis and increase the threat to people in every single country. The G20 must consign this self-defeating approach to the scrap heap.